IRB
Infrastructure Developers has announced the following results for the quarter
ended December 31, 2015 (YOY)
IRB
Infrastructure Ltd Q3FY2016 result – Higher execution boosts earnings
The
consolidated revenues for the quarter grew by 38.3% YoY to Rs1, 333.3 crore on
the back of over 65%YoY growth in construction income.
Standalone
The
Company has posted a net profit of Rs108.26 crore Vs Rs15.84 crore.
Total
Income increased from Rs920.95 crore Vs Rs508.48 crore.
UPL Q3 consolidated net profit up 15%
UPL
has announced the following Q3 results for the quarter ended December 31, 2015
Standalone
Net
Profit rose by 45.87% to Rs42.94 crore Vs Rs79.33 crore.
Total
Income increased by 9.14% to Rs1411.93 crore Vs Rs1293.61 crore.
Dr Reddy receives USFDA approval for Zembrace SymTouch
Dr
Reddy receives USFDA approval for Zembrace SymTouch (sumatriptan succinate)
injection for acute treatment of migraines in adults – Positive
DRL
receives USFDA nod for Zembrace SymTouch (sumatriptan succinate) injection, a
drug-device combination product intended for treatment of acute migraine
episodes in adults.
NTPC Q3: Net Profit At Rs2493 Cr
NTPC
Q3: Net Profit At Rs2493 Cr
Total
Income At Rs17,413
Deferred
Tax At Rs485.3 Cr Vs Rs65.7 Cr (YoY)
EBITDA
At Rs4,624 Cr
EBITDA
Margin At 26.6%
Other
Income At Rs244.7 Cr Vs Rs514 Cr (YoY)
Siemens Q1: Net Profit at Rs114 Cr
Siemens
Q1: Net Profit at Rs114 Cr
Total
Income at Rs2, 314 Cr
Trans
& Distribution, Rail Contribute Significantly To Order Intake
Order
Intake Increased By 65%.
Get real time advice for Intraday Trading Tips , Share Market Tips , Intraday Equity Tips , Stock Trading tips , Free Intraday Tips , Best Accurate Stock Tips , NSE Stock market Tips and all Maket Updates .
0 comments:
Post a Comment